Shares of Novavax Inc. jumped 17% in trading on Friday after the Food and Drug Administration announced that an advisory committee is set to meet June 7 to examine the benefits and risks of the company's experimental COVID-19 vaccine.
Novavax's protein-based vaccine has been authorized in several countries, including by the U.K. and the European Commission, but is still being reviewed by the FDA.
The company's stock has tumbled 65.6% this year, while the broader S&P 500 is down 10.0%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments